^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Portrazza (necitumumab)

    i
    Other names: IMC-11F8, LY-3012211
    Company:
    Eli Lilly, Nippon Kayaku
    Drug class:
    EGFR inhibitor
    Related drugs:
    2ms
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2023 --> Jun 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    3ms
    Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov)
    P2, N=248, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2025 --> May 2025 | Trial primary completion date: Nov 2025 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Imfinzi (durvalumab) • gefitinib • Koselugo (selumetinib) • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • etoposide IV • Orpathys (savolitinib) • datopotamab deruxtecan (DS-1062a) • Portrazza (necitumumab)
    3ms
    Enhancement of Antitumor Effect by the Combined Use of Anti-EGFR Antibody(Necitumumab)and PD-1 Inhibitor (PubMed, Gan To Kagaku Ryoho)
    Necitumumab enhances antitumor immunity by decreasing the PD-L1 expression; it is expected to improve the prognosis of patients treated with an immune checkpoint inhibitor(ICI)by inhibiting the IL-8 expression. Since the combined effect of necitumumab and PD-L1 inhibitor was confirmed in an in vivo study conducted in transgenic mice, further antitumor effects can be expected by the combined use of necitumumab and ICI.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    PD-L1 expression • CXCL8 expression
    |
    Portrazza (necitumumab)
    5ms
    UCLA l-08: Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • AXL (AXL Receptor Tyrosine Kinase)
    |
    EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)
    5ms
    Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov)
    P2, N=250, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Imfinzi (durvalumab) • gefitinib • Koselugo (selumetinib) • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • etoposide IV • Orpathys (savolitinib) • datopotamab deruxtecan (DS-1062a) • Portrazza (necitumumab)
    10ms
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    1year
    UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer. (ASCO 2023)
    ONT toxicities are manageable, and the combination has promising preliminary efficacy in refractory EGFR-mutated metastatic NSCLC. Evaluation of phase 2, stage 1 is expected to be completed by April 2023 and will be reported at the meeting. Clinical trial information: NCT04285671.
    Clinical • P1/2 data
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation
    |
    Herceptin (trastuzumab) • Tagrisso (osimertinib) • Portrazza (necitumumab)
    1year
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jul 2023 --> Dec 2023
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    over1year
    Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)
    almost2years
    Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (IASLC-WCLC 2022)
    This is a single-arm, multi-center, open-label phase 1b/2 study to identify the recommended phase 2 dose (RP2D), safety, tolerability, and preliminary efficacy of the combination of osimertinib, necitumumab, and trastuzumab (ONT) in adults with histologically confirmed, metastatic NSCLC with an activating and sensitizing EGFR mutation who have progressed on osimertinib. ONT toxicities are manageable, and the combination has promising preliminary efficacy in EGFR-mutated metastatic NSCLC patients. The trial will continue to enroll.
    P1/2 data
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Herceptin (trastuzumab) • Tagrisso (osimertinib) • Portrazza (necitumumab)
    almost2years
    A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (clinicaltrials.gov)
    P1, N=29, Completed, Eli Lilly and Company | Active, not recruiting --> Completed | N=74 --> 29 | Trial completion date: Nov 2022 --> May 2022
    Trial completion • Enrollment change • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Portrazza (necitumumab)
    2years
    Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study. (ASCO 2022)
    Osi/Neci is feasible and tolerable at the RP2D. EGFR ctDNA was detectable at baseline in the majority of pts with decrease in AF on treatment. Osi/Neci was active in select settings of EGFR-TKI resistance, meeting its prespecified efficacy endpoint in T790Mneg PD on 1st/2nd gen TKI as last therapy (ExC A), EGFR ex20ins post-chemo (ExC D) and PD on 1L osimertinib (ExC E).
    Clinical • P1 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    2years
    Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=22, Terminated, Vanderbilt-Ingram Cancer Center | N=60 --> 22 | Trial completion date: Jul 2023 --> Mar 2022 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Mar 2022; Low accrual
    Preclinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M negative
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)
    2years
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jul 2022 --> Jul 2023
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    over2years
    Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients. (PubMed, J Gastric Cancer)
    A QDB-based assay was developed for gastric cancer specimens to measure EGFR protein levels absolutely, quantitatively, and objectively. This assay should facilitate clinical trials aimed at evaluation of anti-EGFR therapies retrospectively and prospectively for gastric cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR overexpression
    |
    Erbitux (cetuximab) • Portrazza (necitumumab)
    over2years
    Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov)
    P2, N=210, Recruiting, AstraZeneca | N=150 --> 210
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Imfinzi (durvalumab) • gefitinib • Koselugo (selumetinib) • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • etoposide IV • Orpathys (savolitinib) • Portrazza (necitumumab)
    over2years
    A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Eli Lilly and Company | Trial completion date: Nov 2021 --> Nov 2022
    Clinical • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Portrazza (necitumumab)
    over2years
    Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov)
    P2, N=150, Recruiting, AstraZeneca | Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: May 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Imfinzi (durvalumab) • gefitinib • Koselugo (selumetinib) • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • etoposide IV • Orpathys (savolitinib) • Portrazza (necitumumab)
    over2years
    INSPIRE: First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (clinicaltrials.gov)
    P3, N=633, Completed, Eli Lilly and Company | Trial completion date: Jul 2021 --> Dec 2020 | Active, not recruiting --> Completed
    Clinical • Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR overexpression
    |
    cisplatin • pemetrexed • Portrazza (necitumumab)
    over2years
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jul 2021 --> Jul 2022
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    almost3years
    A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Eli Lilly and Company | Trial completion date: May 2021 --> Nov 2021
    Clinical • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Portrazza (necitumumab)
    3years
    Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (clinicaltrials.gov)
    P2, N=150, Recruiting, AstraZeneca | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> May 2025
    Clinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • carboplatin • Imfinzi (durvalumab) • gefitinib • Alecensa (alectinib) • Retevmo (selpercatinib) • pemetrexed • Orpathys (savolitinib) • Portrazza (necitumumab)
    3years
    Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=26, Recruiting, Jonsson Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Portrazza (necitumumab)
    over3years
    Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Dec 2021 --> Jul 2022
    Clinical • Preclinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M negative
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)
    over3years
    INSPIRE: First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (clinicaltrials.gov)
    P3, N=633, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2021 --> Jul 2021
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR overexpression
    |
    cisplatin • pemetrexed • Portrazza (necitumumab)
    over3years
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2021 --> Jul 2021
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    over3years
    [VIRTUAL] Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors (IASLC-WCLC 2020)
    Introduction There are no approved targeted therapies for patients (pts) with EGFR mutated NSCLC who develop acquired resistance to frontline 3rd generation (gen) tyrosine kinase inhibitors (TKI) osimertinib (osi), 2nd line osi (T790MPOS after 1st/2nd gen TKI), or frontline 1st/2nd gen TKI and T790MNEG. Conclusion The combination of afatinib and necitumumab had expected toxicities of rash and diarrhea. Trial is ongoing, and the MTD of afatinib 40 mg and necitumumab 600 mg is being tested in 3 dose expansion cohorts.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • Portrazza (necitumumab)
    over3years
    Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials. (PubMed, Ann Palliat Med)
    With a longer PFS and a higher DCR, NC treatment seemed to be more suitable for treating stage IV NSCLC as first-line therapy, especially for those with high EGFR expression, but its AEs could not be ignored.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR overexpression
    |
    Portrazza (necitumumab)
    over3years
    INSPIRE: First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (clinicaltrials.gov)
    P3, N=633, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jul 2020 --> Jan 2021
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR overexpression
    |
    cisplatin • pemetrexed • Portrazza (necitumumab)
    over3years
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jul 2020 --> Jan 2021
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    almost4years
    Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Vanderbilt-Ingram Cancer Center | Suspended --> Recruiting
    Clinical • Enrollment open • Preclinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M negative
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)
    almost4years
    Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Suspended, Vanderbilt-Ingram Cancer Center | Recruiting --> Suspended
    Clinical • Preclinical • Trial suspension
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M negative
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)
    4years
    [VIRTUAL] Phase I trial of combination afatinib (Afat) and necitumumab (Neci) in EGFR mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to first or third generation EGFR tyrosine kinase inhibitors (TKIs). (ASCO 2020)
    No abstract available
    P1 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)
    4years
    A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Eli Lilly and Company | Trial completion date: May 2020 --> May 2021
    Clinical • Trial completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR T790M
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Portrazza (necitumumab)
    4years
    Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. (PubMed, Lung Cancer)
    Results suggest modest benefits of second-line necitumumab and pembrolizumab combination therapy in patients with Stage IV NSCLC. Safety profiles were consistent with class effects typical of epidermal growth factor receptor inhibitors and immunotherapies with no additive toxicities.
    Clinical • Journal • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Portrazza (necitumumab)
    4years
    SQUIRE: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin (clinicaltrials.gov)
    P3, N=1093, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2020 --> Jul 2020
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • EGFR mutation • EGFR expression • EGFR overexpression • EGFR mutation + KRAS mutation
    |
    cisplatin • gemcitabine • Portrazza (necitumumab)
    4years
    INSPIRE: First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin (clinicaltrials.gov)
    P3, N=633, Active, not recruiting, Eli Lilly and Company | Trial completion date: Jan 2020 --> Jul 2020
    Clinical • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR overexpression
    |
    cisplatin • pemetrexed • Portrazza (necitumumab)
    over4years
    Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Mar 2021 --> Dec 2022 | Trial primary completion date: Mar 2020 --> Dec 2021
    Clinical • Preclinical • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M negative
    |
    Gilotrif (afatinib) • Portrazza (necitumumab)